

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: NDA 19777/S17

CHEMISTRY REVIEW(S)

MAY 26 1993

| | | | |
|---|---|--|---|
| CHEMIST'S REVIEW | | 1. ORGANIZATION HFD-110 | 2. NDA Number 19-777 |
| 3. Name and Address of Applicant (City & State) Zeneca Inc. Wilmington, DE 19897 | | 4. Supplement(s) Number(s) Date(s) S-017 12 Feb 93 | |
| 5. Drug Name Zestril | 6. Nonproprietary Name Lisinopril | | 7. Amendments & Other (reports, etc) - Dates Amendment 13 Apr 93 |
| 8. Supplement Provides For: Manufacture of 5, 10, 20 and 40 mg Zestril Tablets by IPR Pharmaceuticals, Inc., Carolinas, PR, a division of Zeneca, Ltd. (UK). | | | |
| 9. Pharmacological Category Antihypertensive | 10. How Dispensed <input checked="" type="checkbox"/> Rx <input type="checkbox"/> OTC | | 11. Related IND(s)/ NDA(s)/DMF(s) NDA 19-558 Prinivil, Merck |
| 12. Dosage Form(s) TCM | 13. Potency(ies) 2.5, 5, 10, 20, 40 mg | | |
| 14. Chemical Name and Structure | | | 15. Records/Reports Current <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No Reviewed <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No |
| 16. Comments: The amendment provides responses to the deficiencies noted in the review of the original submission and conveyed to the applicant in a letter dated 1 Apr 93. The deficiencies are repeated followed by the applicant's responses. An approved EER was received from HFD-320 dated 5 May 93. | | | |
| 17. Conclusions and Recommendations: The information provided by the applicant in response to the Agency's letter of 1 Apr 93 is satisfactory. APPROVAL is recommended | | | |
| 18. | | | |
| Name James H.Short | | Date Completed | |
| Distribution: <input checked="" type="checkbox"/> Original Jacket <input type="checkbox"/> Reviewer <input type="checkbox"/> Division File <input type="checkbox"/> CSO | | | |

jhs/5/21/93/N19-777A.S17

R/D Init: RWolters/5/26/93

APR 1 1993

| | | | |
|--|---|---|---|
| CHEMIST'S REVIEW | | 1. ORGANIZATION HFD-110 | 2. NDA Number 19-777 |
| 3. Name and Address of Applicant (City & State) Zeneca Inc. Wilmington, DE 19897 | | 4. Supplement(s) Number(s) Date(s) S-017 12 Feb 93 | |
| 5. Drug Name Zestril | 6. Nonproprietary Name Lisinopril | | 7. Amendments & Other (reports, etc) - Dates |
| 8. Supplement Provides For: Manufacture of 5, 10, 20 and 40 mg Zestril Tablets by IPR Pharmaceuticals, Inc., Carolinas, PR, a division of Zeneca, Ltd. (UK). | | | |
| 9. Pharmacological Category Antihypertensive | 10. How Dispensed <input checked="" type="checkbox"/> Rx <input type="checkbox"/> OTC | | 11. Related IND(s)/NDA(s)/DMF(s) NDA 19-558 Prinivil, Merck |
| 12. Dosage Form(s) TCM | 13. Potency(ies) 2.5, 5, 10, 20, 40 mg | | |
| 14. Chemical Name and Structure | | | 15. Records/Reports Current <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No Reviewed <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No |
| 16. Comments: | | | |
| 17. Conclusions and Recommendations: NOT APPROVABLE The deficiencies noted in the review of this supplement will be conveyed to the applicant. | | | |
| 18. | | | |
| Name James H. Short | | REVIEWER [Signature] | |
| Distribution: <input type="checkbox"/> Original Jacket | | Date Completed 29 Mar 93 | |
| <input type="checkbox"/> Reviewer | | <input type="checkbox"/> Division File <input type="checkbox"/> CSO | |

jhs/3/22/93/N19-777.S17

R/D Init: RWolters/3/31/93